Aptevo Therapeutics Inc. has filed a preliminary proxy statement to announce a special meeting of stockholders, set for December 14, 2026. This meeting is significant as it will address several important proposals aimed at strengthening the company's financial position and governance structure.

The special meeting will take place virtually at 10 a.m. Pacific Time, allowing stockholders to participate from anywhere. This format is designed to facilitate participation while also reducing costs associated with physical meetings.

Among the key proposals to be discussed are:

1. Approval of the issuance of shares that equal 20% or more of the company's outstanding common stock, including securities convertible into common stock.

2. An amendment to the company's certificate of incorporation to implement a reverse stock split of the outstanding common stock at a ratio between 1-for-3 and 1-for-10.

3. Approval of the Sixth Amended and Restated 2018 Stock Incentive Plan.

4. Authorization for the adjournment of the meeting if necessary to solicit additional proxies.

This filing, with accession number 0001193125-26-458711, reflects Aptevo's ongoing efforts to enhance its capital structure and operational flexibility. The proposed reverse stock split is particularly noteworthy, as it could help the company regain compliance with Nasdaq's listing requirements if its stock price has fallen below the minimum threshold.

Aptevo Therapeutics is categorized under the SIC code 2834, which pertains to pharmaceutical preparations. This industry segment is characterized by companies engaged in the research, development, and production of medications and therapeutic solutions.

The outcomes of the proposals discussed in the upcoming meeting could have significant implications for Aptevo's future operations and its ability to attract investment. By addressing these critical issues, the company aims to position itself more favorably in the competitive pharmaceutical landscape.

As the date of the special meeting approaches, stockholders will be closely monitoring the developments and the company's strategic direction. The filing does not specify what happens next following the meeting, leaving stakeholders to await the results of the vote.